Therapeutic response to a novel enzyme-targeting radiosensitization treatment (Kochi Oxydol-Radiation Therapy for Unresectable Carcinomas) in patients with recurrent breast cancer

Aoyama,Nobutaka; Ogawa,Yasuhiro; Yasuoka,Miki; Takahashi,Masao; Iwasa,Hitomi; Miyatake,Kana; Yamanishi,Tomoaki; Hamada,Norihiko; Tamura,Taiji; Nishioka,Akihito; Yamagami,Takuji

doi:10.3892/ol.2016.4589

Therapeutic response to a novel enzyme-targeting radiosensitization treatment (Kochi Oxydol-Radiation Therapy for Unresectable Carcinomas) in patients with recurrent breast cancer

Authors:
- Nobutaka Aoyama
- Yasuhiro Ogawa
- Miki Yasuoka
- Masao Takahashi
- Hitomi Iwasa
- Kana Miyatake
- Tomoaki Yamanishi
- Norihiko Hamada
- Taiji Tamura
- Akihito Nishioka
- Takuji Yamagami
View Affiliations

Affiliations: Department of Diagnostic Radiology and Radiation Oncology, Medical School, Kochi University, Kochi 783‑8505, Japan, Hyogo Prefectural Kakogawa Medical Center, Hyogo 675‑8555, Japan
Published online on: May 16, 2016 https://doi.org/10.3892/ol.2016.4589
Pages: 29-34
Copyright: © Aoyama et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Linear accelerator-based radiotherapy has little effect on the majority of locally advanced neoplasms. Thus, the novel radiosensitizer Kochi Oxydol Radiation Therapy for Unresectable Carcinomas, Type II (KORTUC II), which contains hydrogen peroxide and sodium hyaluronate, was developed. The effectiveness of KORTUC II for the treatment of chemotherapy‑resistant supraclavicular lymph node metastases has been previously demonstrated. The present study evaluated the safety and effectiveness of KORTUC II in patients with recurrent breast cancer. A total of 20 patients (age range, 39‑84 years) were enrolled in the study. The majority of patients underwent positron emission tomography (PET)‑computed tomography (CT) examinations prior to and 1‑7 months following KORTUC II treatment, and every 6 months thereafter when possible. The radiotherapy regimen was 2.75 Gy/fraction, 5 fractions/week, for 16‑18 fractions, with a total radiation dose of 44.00‑49.50 Gy (X‑ray irradiation), or 4.00 Gy/fraction, 3 fractions/week, for 10‑12 fractions, with a total radiation dose of 40.00‑48.00 Gy (electron beam irradiation). The injection of 3‑6 ml of the KORTUC II agent was initiated at the fifth radiotherapy fraction, and was performed twice/week under ultrasonographic guidance. The therapeutic effects were evaluated by PET‑CT examinations prior and subsequent to KORTUC II treatment, which was observed to be well tolerated with minimal adverse effects. Of the 24 lesions presented by the 20 patients, 18 exhibited complete response, 5 partial response, 0 stable disease and 1 progressive disease. The overall survival rate was 100% at 1 year and 95% at 2 years. The mean duration of follow‑up at the end of June 2014 was 51 months. Based on the results of the PET‑CT studies conducted, KORTUC II treatment demonstrated marked therapeutic effects, with satisfactory treatment outcomes and acceptable adverse events.

View Figures

View References

1	Niibe Y, Kuranami M, Matsunaga K, Takaya M, Kakita S, Hara T, Sekiguchi K, Watanabe M and Hayakawa K: Value of high-dose radiation therapy for isolated osseous metastasis in breast cancer in terms of oligo-recurrence. Anticancer Res. 28:3929–3931. 2008.PubMed/NCBI
2	Milano MT, Zhang H, Metcalfe SK, Muhs AG and Okunieff P: Oligometastatic breast cancer treated with curative-intent stereotactic body radiation therapy. Breast Cancer Res Treat. 115:601–608. 2009. View Article : Google Scholar : PubMed/NCBI
3	Niibe Y and Hayakawa K: Oligometastases and oligo-recurrence: The new era of cancer therapy. Jpn J Clin Oncol. 40:107–111. 2010. View Article : Google Scholar : PubMed/NCBI
4	Ogawa Y: Paradigm shift in radiation biology/radiation oncology-exploitation of the “H₂O₂ effect” for radiotherapy using low-LET (linear energy transfer) radiation such as x-rays and high-energy electrons. Cancers (Basel). 8:E282016. View Article : Google Scholar : PubMed/NCBI
5	Ogawa Y, Kubota K, Ue H, Kataoka Y, Tadokoro M, Miyatake K, Tsuzuki K, Yamanishi T, Itoh S, Hitomi J, et al: Phase I study of a new radiosensitizer containing hydrogen peroxide and sodium hyaluronate for topical tumor injection: A new enzyme-targeting radiosensitization treatment, Kochi Oxydol-Radiation Therapy for Unresectable Carcinomas, Type II (KORTUC II). Int J Oncol. 34:609–618. 2009. View Article : Google Scholar : PubMed/NCBI
6	Ogawa Y, Kubota K, Ue H, Tadokoro M, Matsui R, Yamanishi T, Hamada N, Kariya S, Nishioka A, Nakajima H, et al: Safety and effectiveness of a new enzyme-targeting radiosensitization treatment (KORTC II) for intratumoral injection for low-LET radioresistant tumors. Int J Oncol. 39:553–560. 2011.PubMed/NCBI
7	Aoyama N, Ogawa Y, Kubota K, Ohgi K, Kataoka Y, Miyatake K, Tadokoro M, Yamanishi T, Ohnishi T, Hamada N, et al: Therapeutic response to a new enzyme-targeting radiosensitization treatment (KORTUC-SC) for patients with chemotherapy-resistant supraclavicular lymph node metastasis. J Cancer Res Ther. 1:215–219. 2013. View Article : Google Scholar
8	Tokuhiro S, Ogawa Y, Tsuzuki K, Akima R, Ue H, Kariya S and Nishioka A: Development of a novel enzyme-targeting radiosensitizer (KORTUC) containing hydrogen peroxide for intratumoral injection for patients with low linear energy transfer-radioresistant neoplasms. Oncol Lett. 1:1025–1028. 2010.PubMed/NCBI
9	Jette DC, Wiebe LI and Chapman JD: Synthesis and in vivo studies of the radiosensitizer 4-[⁸²Br]bromomisonidazole. Int J Nucl Med Biol. 10:205–210. 1983. View Article : Google Scholar : PubMed/NCBI
10	Coleman CN: Hypoxic cell radiosensitizers: Expectations and progress in drug development. Int J Radiat Oncol Biol Phys. 11:323–329. 1985. View Article : Google Scholar : PubMed/NCBI
11	Lawrence TS, Blackstock AW and McGinn C: The mechanism of action of radiosensitization of conventional chemotherapeutic agents. Semin Radiat Oncol. 13:13–21. 2003. View Article : Google Scholar : PubMed/NCBI
12	Böhm L, Roos WP and Serafin AM: Inhibition of DNA repair by pentoxifylline and related methylxanthine derivatives. Toxicology. 193:153–160. 2003. View Article : Google Scholar : PubMed/NCBI
13	Milas L: Cyclooxygenase-2 (COX-2) enzyme inhibitors as potential enhancers of tumor radioresponse. Semin Radiat Oncol. 11:290–299. 2001. View Article : Google Scholar : PubMed/NCBI
14	Choy H and Milas L: Enhancing radiotherapy with cyclooxygenase-2 enzyme inhibitors: A rational advance. J Natl Cancer Inst. 95:1440–1452. 2003. View Article : Google Scholar : PubMed/NCBI
15	Overgaard J: Clinical evaluation of nitroimidazoles as modifiers of hypoxia in solid tumors. Oncol Res. 6:509–518. 1994.PubMed/NCBI
16	Gerlach NL, Barkhuysen R, Kaanders JH, Janssens GO, Sterk W and Merkx MA: The effect of hyperbaric oxygen therapy on quality of life in oral and oropharyngeal cancer patients treated with radiotherapy. Int J Oral Maxillofac Surg. 37:255–259. 2008. View Article : Google Scholar : PubMed/NCBI
17	Overgaard J: Hypoxic radiosensitization: Adored and ignored. J Clin Oncol. 25:4066–4074. 2007. View Article : Google Scholar : PubMed/NCBI
18	Williamson RA: An experimental study of the use of hyperbaric oxygen to reduce the side effects of radiation treatment for malignant disease. Int J Oral Maxillofac Surg. 36:533–540. 2007. View Article : Google Scholar : PubMed/NCBI
19	Oronsky BT, Knox SJ and Scicinski J: Six degrees of separation: The oxygen effect in the development of radiosensitizers. Transl Oncol. 4:189–198. 2011. View Article : Google Scholar : PubMed/NCBI
20	Wardman P: Chemical radiosensitizers for use in radiotherapy. Clin Oncol (R Coll Radiol). 19:397–417. 2007. View Article : Google Scholar : PubMed/NCBI
21	Nishino M, Jackman DM, Hatabu H, Yeap BY, Cioffredi LA, Yap JT, Jänne PA, Johnson BE and Van den Abbeele AD: New Response Evaluation Criteria in Solid Tumors (RECIST) guidelines for advanced non-small cell lung cancer: comparison with original RECIST and impact on assessment of tumor response to targeted therapy. AJR Am J Roentgenol. 195:221–228. 2010. View Article : Google Scholar
22	Bennett AV, Dueck AC, Mitchell SA, Mendoza TR, Reeve BB, Atkinson TM, Castro KM, Denicoff A, Rogak LJ, Harness JK, et al: National Cancer Institute PRO-CTCAE Study Group: Mode equivalence and acceptability of tablet computer-, interactive voice response system-, and paper-based administration of the U.S. National Cancer Institute's Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE). Health Qual Life Outcomes. 14:242016. View Article : Google Scholar : PubMed/NCBI
23	Oldenborg S, Van Os RM, Van Rij CM, Crezee J, Van de Kamer JB, Rutgers EJ, Geijsen ED, Zum Vörde sive vörding PJ, Koning CC and Van tienhoven G: Elective re-irradiation and hyperthermia following resection of persistent locoregional recurrent breast cancer: A retrospective study. Int J Hyperthermia. 26:136–144. 2010. View Article : Google Scholar : PubMed/NCBI
24	Ben-Yosef R, Vigler N, Inbar M and Vexler A: Hyperthermia combined with radiation therapy in the treatment of local recurrent breast cancer. Isr Med Assoc J. 6:392–395. 2004.PubMed/NCBI
25	Zagar TM, Oleson JR, Vujaskovic Z, Dewhirst MW, Craciunescu OI, Blackwell KL, Prosnitz LR and Jones EL: Hyperthermia combined with radiation therapy for superficial breast cancer and chest wall recurrence: A review of the randomised data. Int J Hyperthermia. 26:612–617. 2010. View Article : Google Scholar : PubMed/NCBI